PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
October 29, 2026

Attendance: *Microsoft Teams Meeting*
Dr. Paul Aitken, Medical Director; Vanessa Amilcar, Pharmacy Student Intern; Rojin Baniasadi, Pharmacy Resident; Kelly Bartolone, Staff/Clinical Pharmacist; Niki Bautista, Pharmacy Student Intern; Juby Benny, Pharmacy Student Intern; Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Lauren Culbert, Pharmacy Student Intern; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Lauren Grantz, Administrator Outpatient Pharmacy Services, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Samantha Jackson, Formulary Pharmacist; Ruth John, Staff/Clinical Pharmacist; Sheenu Joseph, Staff/Clinical Pharmacist; Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Derek McFerran, Vice President, Pharmacy Operations; Michele McKenna, Staff/Clinical Pharmacist; Lisa Murray, Staff/Clinical Pharmacist; Claudia Pinketti, Staff/Clinical Pharmacist; Ryan Prager, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Tara Swartz, Staff/Clinical Pharmacist; Michelle Tran, Pharmacy Resident; Dr. Frank Urbano, Medical Director; Fallan Vaisberg, Formulary Pharmacist; Reena Varghese, Staff/Clinical Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: *Dr. Neal Demp, Community Behavior Health; Kristen DeSorte, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Hailey Fry, Centennial Pharmacy; Jessica Hoang-Le, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Brandi Mahler, Supervisor Pharmacy Technicians; Kateryna Puia, Clinical Programs Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health*

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
Minutes Review/Approval	*D. Dolores presented the minutes from the August 2026 meeting to the Committee for review.*	*The Committee approved the minutes from our last meeting as presented.*	*D. Dolores*	*Resolved*

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
Policies and Procedures	*D. Dolores reviewed the annual Policies and Procedure review and updates.* • *Pharmacy Prior Authorization* • *Pharmacy Operations and Responsibilities* • *Pharmacy Formulary Management* • *Pharmacy Vendor Management* • *Pharmacy and Therapeutics (P&T) Committee* • *Drug Utilization Review*	*Informational*	*D. Dolores*	
Open Enrollment	*D. Dolores presented dates for open enrollment 11/1/2026 through 12/15/2026*	*Informational*	*D. Dolores*	

II. 2026 Formulary Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
2026 Formulary Additions	*The Committee reviewed the 2026 Formulary Additions. The Committee approved as presented.* • *Brivaracetam 10 MG/ML solution - T3, ST, 600/ 30 days* • *Dextromethorphan-Quinidine 20-10 MG capsule - T4, PA, QL 60/30 days* • *Sitagliptan-metformin 50-500 mg ER tablet 24H - T3, QL 60/30 days* • *Sitagliptan-metformin 50-1000 mg ER tablet 24H - T3, QL 60/30 days* • *Sitagliptan-metformin 100-1000 mg ER tablet 24H - T3, QL 30/30 days*	*The Committee approved as presented.*	*J. Zubrzycki*	*Resolved*

III. 2027 Formulary Updates

2027 Proposed Formulary Additions	*The Committee reviewed the 2027 Proposed Formulary Additions.* • *Advair HFA 45-21 mcg/act Aerosol - T3, QL 12/30 days* • *Advair HFA 115-21 mcg/act Aerosol - T3, QL 12/30 days* • *Advair HFA 230-21 mcg/act Aerosol - T3, QL 12/30 days*	*The Committee approved as presented.*	*J. Zubrzycki*	*Resolved*

	• *Ajovy 225 MG/1.5ML soln a-inj - T3, PA, QL 1.5/28 days* • *Ajovy 225 MG/1.5ML soln prsyr - T3, PA, QL 1.5/28 days* • *Dulera 50-5 mcg/act aerosol - T3, QL 13/30 days* • *Dulera 100-5 mcg/act aerosol - T3, QL 13/30 days* • *Dulera 200-5 mcg/act aerosol - T3, QL 13/30 days* • *Incruse Ellipta 62.5 mcg/act aer pow ba - T3, QL 30/30 days* • *Ipratropium Bromide HFA 17 mcg/act aero soln - T3, QL 25.8/30 days* • *Tiotropium bromide 18 mcg capsule - T3, QL 30/30 days*			
2027 Formulary Proposed Updates - Inflammatory Conditions	*The Committee reviewed 2027 Formulary Proposed Updates - Inflammatory Conditions.* • *adalimumab-adbm (BI, Quallent)* • *adalimumab-adaz (Sandoz)* • *Simlandi (Teva)* • *Imuldosa (Accord)* • *Ustekinumab-ttwe (Quallent)* • *Yesintek (Biocon)* • *Orencia* • *Kineret* • *Otezla/Otezla XR* • *Olumiant* • *Bimzelx* • *Siliq* • *Cimzia* • *Sotyktu* • *Enbrel* • *Velsipity* • *Simponi 100mg* • *Simponi 50mg* • *Tremfya* • *Icotyde* • *Zymfentra* • *Taltz* • *Omvoh* • *Zeposia* • *Skyrizi* • *Kevzara* • *Cosentyx*	*The Committee approved as presented.*	*H. McCaffrey*	*Resolved*

	• *Ilumya* • *Actemra* • *Avtozma SC* • *Tyenne SC* • *Tofacitinib* • *Xeljanz* • *Rinvoq* • *Entyvio*			
2027 Proposed Formulary Removals	*The Committee reviewed 2027 Proposed Formulary Removals.* • *Asmanex HFA - Arnuity Ellipta, fluticasone* • *Astagraf XL - Generic preferred* • *Bevespi - Anoro Ellipta* • *Bosulif tablet - Generic preferred* • *Edurant - Generic preferred* • *Emcyt - Product discontinued* • *Flutamide - Product discontinued* • *Janumet/Janumet XR - Generic preferred* • *Januvia - Generic preferred* • *Levemir - Product discontinued* • *Narcan - Generic preferred* • *Norvir 80mg/ml solution - Product discontinued* • *Nuedexta - Generic preferred* • *Opsumit - Generic preferred* • *Phexxi - Rebranded (Phexx preferred)* • *Selarsdi - Preferred ustekinumab agents* • *Simponi Aria 50mg/4ml solution - 100 mg preferred* • *Simponi 50mg/ 0.5ml - 100 mg preferred* • *Truseltiq - Product discontinued* • *Turalio 200mg capsule - Product discontinued* • *Vigpoder - Generic preferred* • *Xarelto 1mg/ml recon susp - Generic preferred* • *Xarelto 2.5mg tablet - Generic preferred* • *Xeljanz - Generic preferred* • *Xeljanz XR - Generic preferred*	*The Committee approved as presented.*	*J. Zubrzycki*	*Resolved*

IV. 2027 Prior Authorization Review/Update

Prior Authorization Criteria Review	*The Committee reviewed the 2027 Prior Authorization Criteria. The Committee approved as presented.* • *Adalimumab* • *Analgesics Opioid Long-Acting* • *Analgesics Opioid Short-Acting* • *Bexarotene Gel* • *Cayston* • *Dupixent* • *Early Refills* • *Enbrel* • *Epclusa (prev sofosbuvir-velpatasvir)* • *Evrysdi* • *Fasenra* • *Gattex* • *GLP-1 Agonists* • *Harvoni (ledipasvir-velpatasvir)* • *Kevzara* • *Lanreotide Extended Release (NF)* • *Mifepristone (NF)* • *Miglustat* • *Non-Formulary Exceptions and Tier Exceptions Policy* • *Otezla* • *Pegasys* • *Preventive Services* • *Quantity Limit Exceptions* • *Repatha* • *Rinvoq* • *Simponi* • *Sivextro* • *Skyrizi* • *Sovaldi* • *Step Therapy Exceptions* • *Strensiq* • *Taltz* • *Tofacitinib-Xeljanz* • *Tolvaptan* • *Topical PDE-4 Inhibitors* • *Tremfya* • *Ustekinumab* • *Velsipity*	*The Committee approved as presented.*	*J. Zubrzycki* *H. McCaffrey* *F. Vaisberg* *S. Staffa* *M. Prokopets* *Y. Hedrick*	*Resolved*

	• *Vosevi* • *Xolair* • *Zepatier* *Prior authorization criteria will continue for the 2027 benefit year.*			

V. New Drug Review	*(Presented in New Drug Review for Medicaid.)* *The following new products were reviewed and will be kept as non-formulary:* • *Hovilpri (pritelivir) Tablets* • *Emcitate (tiratricol) Tablets for Oral Suspension* • *Atebrioz (zilurgisertib) Tablets* • *Juvmo (tavapadon) Tablets* • *Lamlique (lamotrigine) Oral Suspension* • *Onswik (insulin efsitora alfa-gobe) Injection* • *Lyrfigtu (lirafugratinib) Capsules* • *Omcazio (cabozantinib) Capsules* • *Etcamah (camizestrant) Tablets* • *Mimrylo (rusfertide) Lyophilized Powder for Injection* • *Bixlenvo (bictegravir and lenacapavir) Tablets* • *Lisraya (brepocitinib) Tablets* • *Rasonque (daraxonrasib) Tablets* • *Zenbexus (iberdomide) Capsules* • *Orzeyful (oveporexton) Tablets*	*The Committee approved as presented and recommended.*	*R. Baniasadi* *M. Tran*	*Resolved*

VI. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2027**.**



11/11/2026

Danielle Dolores, Director of Pharmacy Services

Date